文献速递肝胆胰外科围术期管理与 ERAS

非标杆肝门部胆管癌的手术结局:日本高容量中心多中心研究

Surgical Outcomes of Non-Benchmark Perihilar Cholangiocarcinoma: A Multicenter Study from High-Volume Centers in Japan.
PubMed 文献 · Ann Surg · 2026-02-19

该多中心队列纳入2014至2018年日本6家高容量中心648例根治性切除的肝门部胆管癌患者,其中412例(64%)为非标杆(non-BM)病例。非标杆患者中位手术时间644分钟、出血1185 mL、术后住院31天,均超过标杆阈值,但肝衰竭B/C级16.7%、胆漏22.8%、院内死亡2.9%仍在标杆参考值内,中位总生存46.0个月。

要点

  • 非标杆肝门部胆管癌在高容量中心仍可获得可接受的围术期与远期结局。
  • 非标杆亚组分层有预后价值:医学、外科、双重亚组5年生存率分别为50.5%、34.1%、15.4%。
  • 左三区肝切除在所有术式中死亡率最高(9.5%)。

核心结论

  • 尽管手术复杂度和患者相关危险因素增加,非标杆肝门部胆管癌患者在高容量经验中心治疗仍可获得可接受的围术期和长期结局。
  • 按非标杆亚组分层可提供有意义的预后信息,可能有助于指导复杂肝门部胆管癌的手术决策。

研究设计与样本

  • 2014至2018年日本6家高容量中心648例根治性切除肝门部胆管癌患者的多中心队列研究。
  • 412例(64%)归为非标杆,236例(36%)归为标杆,按既定手术和医学排除标准分类。
  • 分析围术期和肿瘤学结局并与文献既往报告的标杆阈值比较,非标杆病例进一步分为外科、医学和双重亚组。

主要发现

  • 非标杆患者中位手术时间644分钟、术中出血1185 mL、术后住院31天,均超过标杆阈值。
  • 多数术后结局仍在标杆参考值内,包括肝切除后肝衰竭B/C级16.7%、胆漏22.8%、院内死亡2.9%。
  • 中位总生存46.0个月,1年、3年和5年生存率分别为85.8%、55.0%和37.1%。
  • 亚组分析显示生存随复杂度增加而下降:5年生存率医学亚组50.5%、外科亚组34.1%、双重非标杆亚组15.4%。
  • 左三区肝切除在所有术式中死亡率最高(9.5%)。

临床怎么用

  • 非标杆肝门部胆管癌患者在高容量中心仍可考虑根治性手术,围术期和远期结局可接受。
  • 术前可按非标杆亚组(医学、外科、双重)分层评估预后并辅助手术决策。
  • 左三区肝切除死亡率较高(9.5%),选择该术式时需谨慎评估风险。

局限性

  • 非标杆病例来自日本6家高容量中心,结论外推至低容量中心需谨慎。
  • 非标杆亚组分析为分层比较,样本量和统计效能有限。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To evaluate short- and long-term surgical outcomes in non-benchmark (non-BM) patients with perihilar cholangiocarcinoma (pCCA) using a multicenter cohort from Japan. BACKGROUND: Benchmark (BM) criteria have been proposed to standardize surgical outcomes in complex hepatopancreatobiliary procedures. However, BM studies typically exclude patients with significant medical comorbidities or those requiring technically demanding procedures. As a result, the majority of real-world pCCA cases, classified as non-BM, remain underrepresented in the literature, and their outcomes are insufficiently characterized. METHODS: Between 2014 and 2018, a total of 648 patients underwent curative intent resection for pCCA at six high volume centers in Japan. Among them, 412 patients (64%) were categorized as non-BM and 236 patients (36%) as BM according to established surgical and medical exclusion criteria. Perioperative and oncologic outcomes were analyzed and compared with benchmark thresholds previously reported in the literature. Non-BM cases were further stratified into surgical, medical, and dual subgroups for subgroup analysis. RESULTS: The median operative time (644 minutes), intraoperative blood loss (1185 mL), and postoperative hospital stay (31 d) exceeded BM thresholds. Nevertheless, most postoperative outcomes, including Grade B/C post-hepatectomy liver failure (16.7%), bile leakage (22.8%), and in-hospital mortality (2.9%), remained within benchmark reference values. The median overall survival was 46.0 months, with 1-, 3-, and 5-year survival rates of 85.8%, 55.0%, and 37.1%, respectively. Subgroup analysis revealed decreasing survival with increasing complexity: 5-year survival rates were 50.5% in medical, 34.1% in surgical, and 15.4% in dual non-BM patients. Notably, left trisectionectomy was associated with the highest mortality (9.5%) among all procedures. CONCLUSIONS: Despite increased surgical complexity and patient-related risk factors, non-BM pCCA patients can achieve acceptable perioperative and long-term outcomes when treated at experienced, high-volume centers. Stratification by non-BM subgroup provides meaningful prognostic insight and may help guide surgical decision-making in complex pCCA cases.

来源:Ann Surg,查看原文。版权归原作者所有。

引用

  1. Sugiura T, Kawakatsu S, Noji T, et al. Surgical Outcomes of Non-Benchmark Perihilar Cholangiocarcinoma: A Multicenter Study from High-Volume Centers in Japan. Ann Surg. 2026. PMID: 41709362. doi:10.1097/SLA.0000000000007033

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。